News

Wednesday 30th August 2023

MELODY: Study finds immunosuppressed people make antibodies after COVID-19 vaccination

People with weakened immune systems, including those with Scleroderma, are at increased risk of developing a severe infection after being exposed to Covid-19. Vaccinations and booster doses have been offered to immunosuppressed patients since the roll-out of the NHS vaccination programme in 2020. But how well do they work in people who have weakened immune systems? Read on to hear the exciting findings from the MELODY study!

Read Article

Tuesday 9th August 2022

The Decode Scleroderma Study

72 people have signed up for this new trial for people living with diffuse scleroderma and now this clinical study, to test a new investigational drug for use in Diffuse Scleroderma, is ready to start.

Read Article

Monday 1st August 2022

SRUK supports the call on the UK Government to provide Evusheld - a preventative antibody treatment for COVID-19

Evusheld is an antibody treatment designed to prevent patients from contracting COVID-19, and can provide protection for immunocompromised and immunosuppressed people that haven’t mounted a proper response to the vaccine. SRUK is supporting the call for the UK Government to procure and provide Evusheld to patients in the UK. Find out about how you can help on this page.

Read Article

Thursday 26th August 2021

Just in time! UK approves new COVID-19 treatment for immunocompromised individuals

As OCTAVE study sheds light on the reduced immune response in those with chronic illness, the new antibody treatment from Regeneron and Roche could be of great benefit for those who are immunosuppressed or immunocompromised.

Read Article

Friday 6th August 2021

Utilizing Ultrasound

Dr Victoria Flower was awarded funding by SRUK to research non-invasive methods of skin assessment in scleroderma. Last month, her work was published in The Journal of Rheumatology, discussing the potential use of High Frequency Ultrasound as a more objective and detailed measure of skin involvement in scleroderma.

Read Article

Tuesday 3rd August 2021

Johnny Howley's 3 Peaks Challenge

A father from Greater Manchester, whose six-year-old daughter has the rare autoimmune disease scleroderma, has raised more than £7,000 for SRUK to help fund research into the condition

Read Article

Wednesday 26th August 2020

Back To Life - The Psychological Journey Towards a 'New Normal'

Dr. Jo Daniels looks at coping strategies to help in adjusting to the new 'normal' as we resume our daily activities. Based on cognitive behavourial therapy techniques, these simple steps can help us all to feel a little bit more in control as life moves on.

Read Article

Friday 21st August 2020

Findings of nintedanib's safety and tolerability published

A team of researchers based in the USA, UK, Germany, Switzerland and Japan sought to examine the results of the SENSCIS trial to assess the safety and tolerability of nintedanib in people with SSc-ILD.

Read Article

Tuesday 4th August 2020

Evidence for utilising role-play workshops for the education of rare diseases

A research team based at Lille University implemented a simulation-based workshop to assess if there would be a positive change in the ability of medical students to recognise Raynaud's and scleroderma.

Read Article

Friday 30th August 2019

The future of systemic sclerosis classification

A recent review published in Nature Rheumatology focused on research into the classification of scleroderma, which suggests that the current classification does not capture the heterogeneity of the condition.

Read Article